Is Epigral overvalued or undervalued?

As of 3 October 2025, Epigral's valuation grade has moved from fair to expensive, indicating a shift towards overvaluation. The company is currently assessed as overvalued based on its PE ratio of 17.48, an EV to EBITDA of 11.55, and a PEG ratio of 0.26. These ratios suggest that while the company has strong returns on capital and equity, its current pricing does not reflect an attractive investment opportunity. In comparison to its peers, Epigral's PE ratio is significantly lower than that of Solar Industries, which stands at 99.31, and Gujarat Fluoroch at 65.34, both categorized as very expensive. On the other hand, Godrej Industries, which is rated attractive, has a PE ratio of 38.87. Additionally, Epigral's recent stock performance shows a decline of 23.53% over the past year, contrasting with a slight decline of 1.56% in the Sensex, further reinforcing the view that Epigral is overvalued in its current market position.